MULPLEO

This brand name is authorized in Austria, Estonia, Spain, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug MULPLEO contains one active pharmaceutical ingredient (API):

1 Lusutrombopag UNII 6LL5JFU42F - LUSUTROMBOPAG

Lusutrombopag is an orally active TPO receptor agonist. Lusutrombopag acts on the haematopoietic stem cells and on the transmembrane domain of human TPO receptors expressed in megakaryocytes, to stimulate the megakaryocyte to proliferate and differentiate via the similar signal transduction pathway for up-regulating production used by endogenous TPO, thus leading to thrombocytopoiesis. Read about Lusutrombopag

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MULPLEO Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BX07		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1789836
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1181348001
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 379086
Country: IT	Agenzia del Farmaco	Identifier(s): 047622016
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087074
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100416909